Chicago, Illinois--(Newsfile Corp. - October 15, 2019) - Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), will be presenting at the 5th Benzinga Cannabis Capital Conference in Chicago October 22-23 before an audience of well-vetted public and private companies, and an audience of fellow institutional, family office and accredited investors looking for the right opportunities in a crowded and volatile market. Investment opportunities abound.
For more information and/or to register for the conference please visit: https://benzingacannabisconference.com/chicago/?utm_source=newsfile&utm_medium=press_release&utm_campaign=newsfile
About the Conference
The Benzinga Cannabis Capital Conference is the premier gathering of cannabis entrepreneurs and investors in North America. No other conference offers the level of access and seamlessness of interaction between entrepreneurs building future billion-dollar cannabis enterprises and the investors whose capital will make that happen.
These elite events offer entrepreneurs and investors the once-in-a-lifetime opportunity to network, make deals and learn from influencers, policymakers and trailblazers. Benzinga is the go-to source for investors who need the latest news in the cannabis sector, and frequently breaks exclusive coverage on celebrity cannabis entrepreneurs and commentary from leading political and business figures.
Tickets for the event are on-sale and going fast. Entrepreneurs and those interested in investing in cannabis can purchase tickets here.
Benzinga is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street's top traders. Benzinga provides timely, actionable ideas that help users navigate even the most uncertain and volatile markets – in real-time with an unmatched caliber. From breakouts to unusual volume, analyst ratings, futures and options, Benzinga is the leading full-service, one-stop shop for investors of all stripes and styles.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48606